HENDERSON, NV / ACCESSWIRE / February 20, 2019 / Biotech may have had a hard 2018, but the sector is making up for lost time at the start of this year. This may be just getting started as many fund managers are underweight in the industry and may have to chase this run. One more under the radar biotech that tops our list due to their potential in two huge markets is BioRestorative Therapies, Inc. (BRTX). Their BRTX-100 has shown positive results in both preclinical animal and human studies as a non-opioid chronic lower back pain treatment and their ''ThermoStem'' treatment targets the obesity. BioRestorative has an open IND (Investigational New Drug) and has agreed with the FDA on a Phase 2 trial protocol that is targeted to start Q1 of 2019 (this quarter). Since there could be news any day, it'd be wise to start your research immediately.
Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), Outlook Therapeutics, Inc. (OTLK), CorMedix, Inc. (NYSE American: CRMD), Histogenics Corporation (NASDAQ: HSGX), and Amarin Corporation plc (AMRN).
The Global Chronic Low Back Pain Market is relied upon to achieve an estimation of US$ 9.19 billion by 2025, developing at a CAGR of 5.1% amid the forecast time frame of 2017-2025. BioRestorative Therapies, Inc. (BRTX) (Market Cap: $9.241M, Share Price: $0.70), a life sciences company focused on stem cell-based therapies as we mentioned above, is working on their BRTX-100 solution.
The company is also developing a therapy to fight the obesity epidemic. Their ''ThermoStem'' uses brown adipose (fat) derived stem cells to generate brown adipose tissue (''BAT''). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan.
Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.
Outlook Therapeutics, Inc. (OTLK) (Market Cap: $117.982M, Share Price: $1.32) recently announced that it closed on the final tranche (of four) of its $20.0 million private placement of common stock to BioLexis Pte. Limited (BioLexis), the Company's strategic business partner and largest investor, receiving $4.0 million of cash proceeds in exchange for the issuance of 4,288,624 shares of common stock at $0.9327 per share.
CorMedix, Inc. (CRMD) (Market Cap: $200.089M, Share Price: $1.90) announced the topline results of the full data set of the Company's Phase 3 LOCK-IT-100 study for Neutrolin® as a catheter lock solution in hemodialysis patients. The Company recently announced the topline results from the interim analysis of the study, which was terminated in August 2018 following the recommendation of the independent Data Safety Monitoring Board (DSMB) because efficacy had been demonstrated and the pre-specified level of statistical significance had been achieved.
Histogenics Corporation (HSGX) (Market Cap: $8.063M, Share Price: $0.13), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, just provided an update on the NeoCart regulatory pathway based on its ongoing dialogue with the U.S. Food and Drug Administration (the FDA). Since the initial Type C meeting in October 2018, Histogenics and the FDA have continued their discussions on the clinical data generated to date, the potential need for any additional supplemental clinical data (which may include longer-term data from the ongoing Phase 3 trial or additional studies) and potential alternative regulatory pathways for the NeoCart Biologics License Application (BLA).
Amarin Corporation plc (AMRN) (Market Cap: $5.664B, Share Price: $17.54) is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl) capsules, Amarin's first FDA approved product, are a unique, highly-pure and stable omega-3 fatty acid product available by prescription.
This article was written by Regal Consulting, LLC (''Regal Consulting''). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. Regal Consulting has been compensated $50,000 cash for February services. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: ACR Communications LLC
View source version on accesswire.com: